Protalix Biotherapeutics (PLX) 1.84 $PLX
Protalix Bio up on positive interim data for Fabry disease candidate
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:27AM CST
PLX: 1.84 (-0.04)
Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data on PRX-102 for Fabry Disease at the WORLD Symposium
GlobeNewswire - Thu Feb 12, 6:36AM CST
New Positive Clinical Data on Cardiac and Kidney Functions
PLX: 1.84 (-0.04)
Protalix Finishes Patient Enrollment for Fabry Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 3:39PM CST
Protalix (PLX) completed patient enrolment in a phase I/II study on its Fabry disease candidate PRX-102.
SHPG: 239.82 (+6.11), OPHT: 51.11 (+0.12), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82)
Protalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry Disease
GlobeNewswire - Mon Feb 02, 6:00AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASE LX), announced today that the Company has completed enrollment in its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. All patients that completed the trial have opted to continue to receive PRX-102 in an open-label extension trial. PRX-102 is a proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme that is designed to be a more stable enzyme than currently marketed enzyme replacement therapies for Fabry disease.
PLX: 1.84 (-0.04)
Hot Stock: Protalix BioTherapeutics, Shares Gain 7.7% (PLX)
Comtex SmarTrend(R) - Thu Jan 08, 10:35AM CST
Protalix BioTherapeutics (AMEX LX) is one of today's best performing low-priced stocks, up 7.7% to $2.24 on 4.2x average daily volume. Thus far today, Protalix BioTherapeutics has traded 1.1 million shares, vs. average volume of 269,000 shares per day. The stock has outperformed the Dow (7.7% to the Dow's 1.6%) and outperformed the S&P 500 (7.7% to the S&P's 1.6%) during today's trading.
PLX: 1.84 (-0.04)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST
NRX: 6.67 (-0.14), BIND: 6.06 (+0.21), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), SIG: 120.19 (+0.36), PBR: 6.98 (+0.44), NBIX: 37.22 (+0.27), PIR: 12.52 (+0.17), VLCCF: 4.15 (-0.06), CONN: 24.69 (-0.07), CYTR: 2.96 (+0.23), PLX: 1.84 (-0.04), MEET: 1.78 (+0.02), INFI: 15.13 (+0.55), CYRN: 2.83 (+0.23), APOL: 25.97 (+0.33), CJJD: 2.59 (-0.01), CRK: 6.09 (+0.46), FOLD: 8.36 (-0.11), GST: 2.89 (unch)
Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease
GlobeNewswire - Thu Jan 08, 6:12AM CST
Meaningful Clinical Benefits Demonstrated Across All Key Disease Parameters
PLX: 1.84 (-0.04)
Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Rises 16% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 8:32AM CST
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise more than 16% on the day.
PLX: 1.84 (-0.04), AFFX: 11.45 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:48AM CST
SD: 2.09 (+0.14), XENT: 23.06 (+0.46), WLL: 38.53 (+2.41), BTE: 19.27 (+0.32), BOTA: 2.60 (-0.06), CNAT: 5.92 (+0.10), WG: 6.69 (+0.28), SN: 15.21 (-0.12), LPI: 13.25 (+0.81), EROC: 2.63 (+0.15), BCLI: 3.86 (-0.02), NDRM: 10.76 (+0.22), SMLR: 4.54 (+0.20), QURE: 19.83 (-0.18), SFY: 2.91 (+0.26), ANTH: 3.84 (+0.06), PLX: 1.84 (-0.04), APRI: 1.84 (-0.08), STXS: 2.27 (+0.13), GST: 2.89 (unch)
Protalix BioTherapeutics Up 19.2%, Shares Break Through Resistance (PLX)
Comtex SmarTrend(R) - Mon Jan 05, 10:05AM CST
Protalix BioTherapeutics (AMEX LX) is one of today's best performing low-priced stocks, up 19.2% to $2.23 on 3.7x average daily volume. Thus far today, Protalix BioTherapeutics has traded 855,000 shares, vs. average volume of 234,000 shares per day. The stock has outperformed the Dow (19.2% to the Dow's -1.2%) and outperformed the S&P 500 (19.2% to the S&P's -1.3%) during today's trading.
PLX: 1.84 (-0.04)
Protalix up on accelerated growth plan
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:30AM CST
PLX: 1.84 (-0.04)
Protalix BioTherapeutics Announces New Strategy for Accelerated Growth
GlobeNewswire - Mon Jan 05, 6:00AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT LX) (TASE LX), announced today the Company's newly implemented strategy for accelerated growth. The strategy centers around prioritizing existing and new pipeline candidates to focus on bio-better products with potentially clinically superior profiles that offer a clear competitive advantage. The following highlights the details of the strategic plan.
PLX: 1.84 (-0.04)
Europe Ad Comm recommends approval of Celgene's Otezla
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:04AM CST
SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82), CELG: 115.88 (+0.16)
Europe Ad Comm supports approval of Genzyme Gaucher drug
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 6:38AM CST
SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82)
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), PLX: 1.84 (-0.04), NLNK: 38.84 (+1.51), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:06AM CST
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), NLNK: 38.84 (+1.51), PLX: 1.84 (-0.04), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
Protalix Should Rise On Pivotal Near-Term Clinical Trial Catalyst And Longer-Term Better Insurance Outlook
Clinically Sound Investor - Seeking Alpha - Tue Oct 28, 3:02PM CDT
Gaucher Disease and Approaches to Its Treatment Gaucher, or Gaucher's, disease (or GD) is a lysosomal storage disease (LSD). Cells take in big molecules like fats, proteins, and complex carbohydrates and have sacs called lysosomes that release...
PLX: 1.84 (-0.04)
CDC issues new guidelines over Ebola
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:10AM CDT
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), NLNK: 38.84 (+1.51), PLX: 1.84 (-0.04), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
Ebola Hits NYC: Time To Panic
Matthew Finston - at Seeking Alpha - Mon Oct 27, 7:45AM CDT
BCRX: 10.06 (-0.09), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), NLNK: 38.84 (+1.51), PLX: 1.84 (-0.04), SMED: 4.75 (-0.04), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch), OSUR: 8.13 (+0.06)
Protalix Bio up on positive interim data for Fabry disease candidate
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:27AM CST
PLX: 1.84 (-0.04)
Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data on PRX-102 for Fabry Disease at the WORLD Symposium
GlobeNewswire - Thu Feb 12, 6:36AM CST
New Positive Clinical Data on Cardiac and Kidney Functions
PLX: 1.84 (-0.04)
Protalix Finishes Patient Enrollment for Fabry Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 3:39PM CST
Protalix (PLX) completed patient enrolment in a phase I/II study on its Fabry disease candidate PRX-102.
SHPG: 239.82 (+6.11), OPHT: 51.11 (+0.12), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82)
Protalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry Disease
GlobeNewswire - Mon Feb 02, 6:00AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASE LX), announced today that the Company has completed enrollment in its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. All patients that completed the trial have opted to continue to receive PRX-102 in an open-label extension trial. PRX-102 is a proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme that is designed to be a more stable enzyme than currently marketed enzyme replacement therapies for Fabry disease. PLX: 1.84 (-0.04)
Hot Stock: Protalix BioTherapeutics, Shares Gain 7.7% (PLX)
Comtex SmarTrend(R) - Thu Jan 08, 10:35AM CST
Protalix BioTherapeutics (AMEX
LX) is one of today's best performing low-priced stocks, up 7.7% to $2.24 on 4.2x average daily volume. Thus far today, Protalix BioTherapeutics has traded 1.1 million shares, vs. average volume of 269,000 shares per day. The stock has outperformed the Dow (7.7% to the Dow's 1.6%) and outperformed the S&P 500 (7.7% to the S&P's 1.6%) during today's trading. PLX: 1.84 (-0.04)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST
NRX: 6.67 (-0.14), BIND: 6.06 (+0.21), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), SIG: 120.19 (+0.36), PBR: 6.98 (+0.44), NBIX: 37.22 (+0.27), PIR: 12.52 (+0.17), VLCCF: 4.15 (-0.06), CONN: 24.69 (-0.07), CYTR: 2.96 (+0.23), PLX: 1.84 (-0.04), MEET: 1.78 (+0.02), INFI: 15.13 (+0.55), CYRN: 2.83 (+0.23), APOL: 25.97 (+0.33), CJJD: 2.59 (-0.01), CRK: 6.09 (+0.46), FOLD: 8.36 (-0.11), GST: 2.89 (unch)
Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease
GlobeNewswire - Thu Jan 08, 6:12AM CST
Meaningful Clinical Benefits Demonstrated Across All Key Disease Parameters
PLX: 1.84 (-0.04)
Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Rises 16% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 8:32AM CST
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise more than 16% on the day.
PLX: 1.84 (-0.04), AFFX: 11.45 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:48AM CST
SD: 2.09 (+0.14), XENT: 23.06 (+0.46), WLL: 38.53 (+2.41), BTE: 19.27 (+0.32), BOTA: 2.60 (-0.06), CNAT: 5.92 (+0.10), WG: 6.69 (+0.28), SN: 15.21 (-0.12), LPI: 13.25 (+0.81), EROC: 2.63 (+0.15), BCLI: 3.86 (-0.02), NDRM: 10.76 (+0.22), SMLR: 4.54 (+0.20), QURE: 19.83 (-0.18), SFY: 2.91 (+0.26), ANTH: 3.84 (+0.06), PLX: 1.84 (-0.04), APRI: 1.84 (-0.08), STXS: 2.27 (+0.13), GST: 2.89 (unch)
Protalix BioTherapeutics Up 19.2%, Shares Break Through Resistance (PLX)
Comtex SmarTrend(R) - Mon Jan 05, 10:05AM CST
Protalix BioTherapeutics (AMEX
LX) is one of today's best performing low-priced stocks, up 19.2% to $2.23 on 3.7x average daily volume. Thus far today, Protalix BioTherapeutics has traded 855,000 shares, vs. average volume of 234,000 shares per day. The stock has outperformed the Dow (19.2% to the Dow's -1.2%) and outperformed the S&P 500 (19.2% to the S&P's -1.3%) during today's trading. PLX: 1.84 (-0.04)
Protalix up on accelerated growth plan
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:30AM CST
PLX: 1.84 (-0.04)
Protalix BioTherapeutics Announces New Strategy for Accelerated Growth
GlobeNewswire - Mon Jan 05, 6:00AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASE LX), announced today the Company's newly implemented strategy for accelerated growth. The strategy centers around prioritizing existing and new pipeline candidates to focus on bio-better products with potentially clinically superior profiles that offer a clear competitive advantage. The following highlights the details of the strategic plan. PLX: 1.84 (-0.04)
Europe Ad Comm recommends approval of Celgene's Otezla
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:04AM CST
SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82), CELG: 115.88 (+0.16)
Europe Ad Comm supports approval of Genzyme Gaucher drug
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 6:38AM CST
SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82)
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), PLX: 1.84 (-0.04), NLNK: 38.84 (+1.51), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:06AM CST
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), NLNK: 38.84 (+1.51), PLX: 1.84 (-0.04), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
Protalix Should Rise On Pivotal Near-Term Clinical Trial Catalyst And Longer-Term Better Insurance Outlook
Clinically Sound Investor - Seeking Alpha - Tue Oct 28, 3:02PM CDT
Gaucher Disease and Approaches to Its Treatment Gaucher, or Gaucher's, disease (or GD) is a lysosomal storage disease (LSD). Cells take in big molecules like fats, proteins, and complex carbohydrates and have sacs called lysosomes that release...
PLX: 1.84 (-0.04)
CDC issues new guidelines over Ebola
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:10AM CDT
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), NLNK: 38.84 (+1.51), PLX: 1.84 (-0.04), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
Ebola Hits NYC: Time To Panic
Matthew Finston - at Seeking Alpha - Mon Oct 27, 7:45AM CDT
BCRX: 10.06 (-0.09), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), NLNK: 38.84 (+1.51), PLX: 1.84 (-0.04), SMED: 4.75 (-0.04), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch), OSUR: 8.13 (+0.06)
